Is Pharma Getting the Best out of Social Media? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Is Pharma Getting the Best out of Social Media?
With social media receiving increased focus as the pharma industry strives to make the most of new communication technologies, we speak with Cognizants Bhaskar Sambasivan to find out where pharma is when it comes to social media implementation and what more should be being done.



Many pharmaceutical companies use social media platforms as channels to distribute press releases and other company announcements. Is the industry exploiting the full potential of these public platforms?

Most Internet users actively use social media. Social networks have transformed the way we communicate and, more importantly, the platform they provide is the largest, most diverse and probably the most powerful medium of communication observed to date.

For the pharmaceutical industry, social networks offer a means to bridge the gap between companies and end users. Approximately 74% of pharmaceutical companies have adopted social media platforms (1) — a number that is significantly higher than the figures for financial services and retail companies. Despite the focus on and increased uptake of social media for businesses purposes, it is only one component in a communication strategy and not a complete solution. The level of adoption and maturity in successfully implementing social media and reaping business benefits is relatively low and inadequate because of various factors. For the pharmaceutical industry, one of the main hurdles is the stringent regulatory environment.

While many pharmaceutical companies do already use platforms like Twitter and Facebook for distributing press releases and other company announcements, these channels are also being used to promote awareness of health issues and diseases, managing corporate affairs, sharing corporate social responsibility initiatives and engaging with customers while providing them with efficient service in real-time.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here